One Nucleus Partner, Agility Life Sciences, has announced a collaborative services agreement with Inaphaea BioLabs. Claire Thompson, CEO of Agility, commented: "This will enable our clients to take the next steps in their development programmes by testing their prototype formulations in the Inaphaea cell based studies. We believe this will be beneficial to both companies as well as to our clients, creating a more comprehensive scientific environment, and accelerating development timelines."